INDICATIONS EYLEA HD ® (aflibercept) Injection 8 mg is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and ...

Submacular hemorrhage is a rare but devastating sequel of choroidal neovascularization, which is a frequent complication of age-related macular degeneration (AMD). It is serious because it interferes ...

Vision recovery similar at 30 days, consistent with other recent randomized studies ...

Central retinal artery occlusion can result in permanent vision loss. Effective treatment is lacking. We conducted a phase 3, double-blind, double-dummy, randomized, controlled trial involving ...

Background: With increasing experience using anti-VEGF therapy for the treatment of neovascular age-related macular degeneration (nAMD), ophthalmologists have shifted away from a "one size fits all" ...

Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) can cause substantial disease burden for patients. Several organizations have published clinical guidelines on ...

Systemic hypertension is a common complication of systemic vasculitis. Signs of hypertensive retinopathy and choroidopathy will vary, depending on the mode of onset and the severity of hypertension.

– RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema – – Approval is based on two Phase III studies demonstrating ...

– Additional U.S. label update across indications includes information on rare post-marketing reports of retinal vasculitis and/or retinal vascular occlusion; reporting rate is in line with other ...